Snipr Biome takes aim at antibiotic resistant bacteria in phase I trial

Danish biotech company Snipr Biome, which is developing a new type of antibiotics using the gene-editing tool CRISPR, is sending its first candidate to clinic. ”It’s a huge day for us,” says CEO Christian Grøndahl.
Photo: Wolfgang Kumm/AP/Ritzau Scanpix
Photo: Wolfgang Kumm/AP/Ritzau Scanpix
by andreas lønstrup, translated by daniel pedersen

Danish biotech firm Snipr Biome announced on Wednesday that the first dose had been administered in a phase I trial with a potentially preventive treatment against E.coli infections in the gut.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading